TY - JOUR
T1 - Visfatin in human pregnancy
T2 - Maternal gestational diabetes vis-à-vis neonatal birthweight
AU - Mazaki-Tovi, Shali
AU - Romero, Roberto
AU - Kusanovic, Juan Pedro
AU - Vaisbuch, Edi
AU - Erez, Offer
AU - Than, Nandor Gabor
AU - Chaiworapongsa, Tinnakorn
AU - Nhan-Chang, Chia Ling
AU - Pacora, Percy
AU - Gotsch, Francesca
AU - Yeo, Lami
AU - Kim, Sun Kwon
AU - Edwin, Samuel S.
AU - Hassan, Sonia S.
AU - Mittal, Pooja
N1 - Funding Information:
Supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS.
PY - 2009/5/1
Y1 - 2009/5/1
N2 - Objective: Adipose tissue dysfunction, characterized by dysregulation of adipokines production and/or secretion, has been implicated in the pathophysiology of type-2 diabetes mellitus, a metabolic complication closely related to gestational diabetes mellitus (GDM). Recently, an association between circulating maternal visfatin, a novel adipokine with metabolic and immunoregulatory properties, and impaired glucose metabolism as well as with altered fetal growth, has been proposed. The aims of this study were to determine whether there is an association between maternal plasma visfatin concentration, GDM, and a large-for-gestational-age (LGA) newborn. Study design: This cross-sectional study, included pregnant women at term in the following groups: 1) normal pregnancy and an appropriate-for-gestational-age (AGA) neonate (n=54); 2) normal pregnancy and an LGA newborn (n=47); 3) GDM and an AGA newborn (n=56); 4) GDM and an LGA newborn (n=45). The study population was further stratified by first trimester BMI (<25 vs. ≥25 kg/m2). Maternal plasma visfatin concentration was determined by ELISA. Parametric and non-parametric statistics were used for analysis. Results: 1) Among women who delivered an AGA neonate, the median maternal plasma concentration of visfatin was higher in patients with GDM than in those with a normal pregnancy; 2) Among women with a normal pregnancy, those who delivered an LGA neonate had a higher median maternal plasma visfatin concentration than those who delivered an AGA neonate; 3) among patients with normal BMI, there were no significant differences in the median maternal plasma visfatin concentration between the four study groups; and 4) maternal GDM, as well as delivery of an LGA neonate were independently associated with a higher maternal plasma visfatin concentrations. Conclusion: The linkage between increased maternal circulating visfatin and the presence of GDM or delivery of an LGA neonate supports the hypothesis that perturbation of adipokines homeostasis may play a role in the pathophysiology of GDM or excess fetal growth.
AB - Objective: Adipose tissue dysfunction, characterized by dysregulation of adipokines production and/or secretion, has been implicated in the pathophysiology of type-2 diabetes mellitus, a metabolic complication closely related to gestational diabetes mellitus (GDM). Recently, an association between circulating maternal visfatin, a novel adipokine with metabolic and immunoregulatory properties, and impaired glucose metabolism as well as with altered fetal growth, has been proposed. The aims of this study were to determine whether there is an association between maternal plasma visfatin concentration, GDM, and a large-for-gestational-age (LGA) newborn. Study design: This cross-sectional study, included pregnant women at term in the following groups: 1) normal pregnancy and an appropriate-for-gestational-age (AGA) neonate (n=54); 2) normal pregnancy and an LGA newborn (n=47); 3) GDM and an AGA newborn (n=56); 4) GDM and an LGA newborn (n=45). The study population was further stratified by first trimester BMI (<25 vs. ≥25 kg/m2). Maternal plasma visfatin concentration was determined by ELISA. Parametric and non-parametric statistics were used for analysis. Results: 1) Among women who delivered an AGA neonate, the median maternal plasma concentration of visfatin was higher in patients with GDM than in those with a normal pregnancy; 2) Among women with a normal pregnancy, those who delivered an LGA neonate had a higher median maternal plasma visfatin concentration than those who delivered an AGA neonate; 3) among patients with normal BMI, there were no significant differences in the median maternal plasma visfatin concentration between the four study groups; and 4) maternal GDM, as well as delivery of an LGA neonate were independently associated with a higher maternal plasma visfatin concentrations. Conclusion: The linkage between increased maternal circulating visfatin and the presence of GDM or delivery of an LGA neonate supports the hypothesis that perturbation of adipokines homeostasis may play a role in the pathophysiology of GDM or excess fetal growth.
KW - Adipokine
KW - Adipose tissue
KW - Appropriate-for-gestational-age (AGA)
KW - Gestational diabetes mellitus (GDM)
KW - Large-for-gestational-age (LGA)
KW - Pre-B cell colony-enhancing factor (PBEF)
KW - Visfatin
UR - http://www.scopus.com/inward/record.url?scp=63849089033&partnerID=8YFLogxK
U2 - 10.1515/JPM.2009.053
DO - 10.1515/JPM.2009.053
M3 - Article
C2 - 19099366
AN - SCOPUS:63849089033
SN - 0300-5577
VL - 37
SP - 218
EP - 231
JO - Journal of Perinatal Medicine
JF - Journal of Perinatal Medicine
IS - 3
ER -